GlaxoSmithKline plc (GSK.L)
| Previous close | 1,380.00 |
| Open | 1,381.60 |
| Bid | 1,350.00 x 0 |
| Ask | 1,420.00 x 0 |
| Day's range | 1,381.60 - 1,399.26 |
| 52-week range | 1,280.92 - 2,746.59 |
| Volume | |
| Avg. volume | 9,487,353 |
| Market cap | 56.799B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 12.77 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.76 (5.48%) |
| Ex-dividend date | 17 Nov 2022 |
| 1y target est | N/A |
- Business Wire
ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
PHILADELPHIA, August 08, 2022--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus
- Business Wire
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
LONDON, July 27, 2022--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.i The approval extends the current indication in the US to include both lupus and ac
- Business Wire
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
PHILADELPHIA, July 11, 2022--GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
